Nasdaq · CIK 0001840439
BMEA Biomea Fusion, Inc.
Insider trading from SEC Form 4. Last filing Dec 15, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Signals
Open-market buys and sells at Biomea Fusion, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 34Weak | Rainer M Erdtmann See Remarks buy | $43k 30,000 shares | +4% | - | |
| 53Moderate | Michael J.M. Hitchcock Interim CEO buy | $99k 100,000 shares | +667% | - | |
| 33Weak | Rainer M Erdtmann See Remarks buy | $55k 50,000 shares | +8% | - |
Transactions
The last 20 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 11, 2025 | Rainer M Erdtmann See Remarks | POpen-market purchase Common Stock | +30,000 | $1.43 | $43k | 723,027 | Dec 15, 2025 |
| Dec 2, 2025 | Michael J.M. Hitchcock Interim CEO | POpen-market purchase Common Stock | +100,000 | $0.99 | $99k | 115,000 | Dec 4, 2025 |
| Nov 28, 2025 | Rainer M Erdtmann See Remarks | POpen-market purchase Common Stock | +40,000 | $1.10 | $44k | 683,027 | Dec 2, 2025 |
| Dec 1, 2025 | Rainer M Erdtmann See Remarks | POpen-market purchase Common Stock | +10,000 | $1.05 | $11k | 693,027 | Dec 2, 2025 |
| Aug 11, 2025 | Michael J.M. Hitchcock Interim CEO | AGrant or award Stock Option (Right to Buy)derivative | +916,434 | $0.00 | $0 | 916,434 | Aug 13, 2025 |
| Jan 28, 2025 | Rainer M Erdtmann See Remarks | GGift Common Stock | -40,000 | $0.00 | $0 | 673,027 | Aug 13, 2025 |
| Jan 31, 2025 | Rainer M Erdtmann See Remarks | GGift Common Stock | -10,000 | $0.00 | $0 | 663,027 | Aug 13, 2025 |
| Jan 31, 2025 | Rainer M Erdtmann See Remarks | GGift Common Stockindirect: By daughter | +10,000 | $0.00 | $0 | 19,400 | Aug 13, 2025 |
| Jan 31, 2025 | Rainer M Erdtmann See Remarks | GGift Common Stock | -10,000 | $0.00 | $0 | 653,027 | Aug 13, 2025 |
| Jan 31, 2025 | Rainer M Erdtmann See Remarks | GGift Common Stockindirect: By son | +10,000 | $0.00 | $0 | 20,000 | Aug 13, 2025 |
| Jan 31, 2025 | Rainer M Erdtmann See Remarks | GGift Common Stock | -10,000 | $0.00 | $0 | 643,027 | Aug 13, 2025 |
| Jan 31, 2025 | Rainer M Erdtmann See Remarks | GGift Common Stockindirect: By daughter | +10,000 | $0.00 | $0 | 20,000 | Aug 13, 2025 |
| Aug 11, 2025 | Rainer M Erdtmann See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +1,246,989 | $0.00 | $0 | 1,246,989 | Aug 13, 2025 |
| Jul 22, 2025 | Julianne Averill director | AGrant or award Stock Option (Right to Buy)derivative | +241,177 | $0.00 | $0 | 241,177 | Jul 24, 2025 |
| Jun 11, 2025 | Elizabeth Faust director | AGrant or award Stock Option (Right to Buy)derivative | +91,970 | $0.00 | $0 | 91,970 | Jun 13, 2025 |
| Jun 11, 2025 | Sumita Ray director | AGrant or award Stock Option (Right to Buy)derivative | +91,970 | $0.00 | $0 | 91,970 | Jun 13, 2025 |
| Jun 11, 2025 | Eric Aguiar director | AGrant or award Stock Option (Right to Buy)derivative | +91,970 | $0.00 | $0 | 91,970 | Jun 13, 2025 |
| Jun 11, 2025 | Bihua Chen director, owner | AGrant or award Stock Option (Right to Buy)derivative | +91,970 | $0.00 | $0 | 91,970 | Jun 13, 2025 |
| Mar 26, 2025 | Michael J.M. Hitchcock Interim CEO | AGrant or award Stock Option (Right to Buy)derivative | +350,000 | $0.00 | $0 | 350,000 | Mar 28, 2025 |
| Nov 30, 2024 | Franco Valle Chief Financial Officer | AGrant or award Common Stock | +495 | $6.15 | $3,046 | 42,995 | Dec 2, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Eric Aguiardirector
- Julianne Averilldirector
- Bihua Chenowner, other, ceo, chair, officer, director
- Rainer M ErdtmannSee Remarks
- Elizabeth Faustdirector
- Michael J.M. HitchcockInterim CEO
- Sumita Raydirector
- Franco ValleChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.